WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer. There are currently no ...

Entering the fourth year of Covid-19, vaccination has become the frontline of protective measures to control the disease, as global nations have all but given up on mass mitigation strategies such as ...

Please provide your email address to receive an email when new articles are posted on . Pancreatic and renal involvement was nearly twice as common in men, who showed more active B-cell responses. The ...

The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) released the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease. It is the first criteria ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Immunoglobulins (Ig) are also known as antibodies. These proteins protect the body against disease. There are many different types of Ig. Certain diseases result in the growth of an excess number of ...

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...